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Nutritional management of gastrointestinal malignancies
The evidence connecting food and gastrointestinal malignancies 
from epidemiological, case-control, and prospective observational 
studies, indicate that determining the independent effects of 
specifi c nutrients is extremely diffi cult, given the many potential 
environmental factors to that need to be considered.1–3 
Nevertheless some associations have been documented. For instance, 
oesophageal cancer has been linked to low intakes of vitamin C, 
selenium and zinc, with a protective effect been afforded by an 
increased fruit and vegetable intake. Meat and fi sh consumption has 
shown inconsistent associations with oesophageal cancer studies.1 
Gastric cancer has been linked to foods preserved with salt or foods 
with a high salt content, while fruit and vegetable intake has been 
shown to have a protective effect against gastric cancer. Green 
tea has shown a protective effect against gastric cancer in several 
studies.4 Japanese studies have shown a strong environmental 
factor in the development of gastric cancer.5 Pancreatic cancer has 
been linked to increased energy intake and obesity.1 Dietary fat,6,7,8 
increased energy intake,9,10,11 processed meats,12 and central obesity 
appear to increase the risk of colon cancer in some studies.  
Nutritional assessment
Nutritional management of a patient with gastrointestinal malignancy 
fi rst begins with an appropriate nutritional assessment, since several 
factors could affect the patient’s nutritional status. Long standing 
nutritional defi ciencies could result in compromised cellular 
immunity which causes an increased risk for infection and delayed 
wound healing after surgery. Patients with the potential to become 
malnourished should be identifi ed as early as possible during the 
treatment process. Nutritional management of these frail patients 
should be goal orientated, trying to correct nutritional defi ciencies. 
It is important to realise that nutritional status will also be affected 
by underlying comorbidities that may increase the patient’s risk for 
nutritional defi cits.1
Assessing the patient’s general nutritional status at the start of 
treatment is imperative.13,14 A complete medical and dietary history 
is probably the best tool to achieve this goal . The important factors 
to assess include dietary and physical examination, anthropometrics 
and laboratory parameters which may refl ect nutrient defi cits. 
Patients that have lost a signifi cant amount of weight, greater that 
10% of initial body weight, and have shown a reduced oral energy 
intake for a period of between two and 24 weeks are at greater risk 
of developing both macronutrient and micronutrient defi ciencies. 
Available evidence indicates that cancer patients with a weight 
loss greater that 10% of their initial body weight have a reduced 
appetite, lower chemotherapy response as well as shorter medial 
survival time.15 The Subjective Global Assessment (SGA) is a clinical 
method that can be used for the evaluation of a patient’s nutritional 
status. The SGA is a reliable tool to use in clinical settings, with an 
80% accuracy.16
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The most signifi cant dietary advice for cancer patients in general, 
is to consume an adequate amount of energy daily in order to 
maintain current body weight, as well as a liberal amount of protein. 
Oral energy intake should be approximately 105–150 kJ/kg/day. 
A protein intake of approximately 1,0–1,5 g/kg/day will be adequate 
to meet the requirements of most non-wasted cancer patients. 
Cancer patients with a weight loss greater than fi ve percent of their 
initial body weight should be advised to increase their daily energy 
intake by an additional 2100 KJ over and above the recommended 
intake of 105–150 kJ/kg/day. In such patients, protein intake should 
be maximised at 1,5 g/kg/day. It is also important to keep in mind that 
due to the malignancy induced infl ammatory response in advanced 
cancer, additional energy and protein intake may not improve lean 
muscle mass.1
Gastrointestinal surgery
Surgery is the treatment of choice in patients with cancer of the 
oesophagus, with radiation and chemotherapy often given pre-
operatively. Side effects of radiation and chemotherapy often result 
in further weight loss. Surgical treatment usually involves a total 
or distal oesophagectomy requiring bilateral vagotomy, proximal 
gastrectomy, and anastomosis of the retained portion of the 
oesophagus to the remaining stomach. Post-operative regurgitation 
of food and bloating are common complications following surgery 
that can result in further weight loss and debilitation. Oesophageal 
strictures can appear post-operatively that often require repeated 
dilatation to ensure adequate food passage. Placing an oesophageal 
stent to improve food and fl uid passage may be a palliative measure 
for non-surgical patients who experience severe dysphasia due to 
oesophageal luminal cancer growth.1,17
Nutrition support of gastrointestinal cancers
In cancer patients requiring gastrointestinal surgery, the benefi t 
of delaying surgery to attain improved nutritional status needs to 
be carefully considered. Nutritional support can be given by either 
intravenous [parenteral nutrition (PN)] or total enteral nutrition 
(TEN). Available literature suggests that severely malnourished 
cancer patients, with a weight loss greater than 10% of their initial 
body weight, will benefi t from preoperative TPN for a duration of 
seven to ten days.18 Although improved mortality has not been 
reported with improved nutritional status, a 10% improvement 
in postoperative complications has been reported in nutritionally 
supported patients when compared to patients who had nutrition 
support. Administration of PN pre-operatively to non-malnourished 
patients is not recommended, as it results in increased PN associated 
complications.19 Nutritional support of the hospitalised cancer 
patient should be commenced as soon as nutritional intake does 
not match daily increased requirements for a period longer than 
seven days. After a fasting period of seven to ten days, a negative 
nitrogen balance is known to occur, which increases the patient’s 
risk for infections and interferes with wound healing. The practicality 
of giving PN for seven to ten days prior to surgery is however often 
a problem.1
Postoperatively, severely malnourished cancer patients, and 
patients with an anticipated inadequate nutritional intake for seven 
days or longer, will benefi t from postoperative TEN, given within 
48 hours after surgery.18 Nutritional improvement appear to be more 
signifi cant with TEN compared to TPN post surgery.20 Patients with 
a pre-operative weight loss greater that 10% of initial body weight 
should ideally have a jejunal feeding tube place at the time of surgery. 
The feeding tube can later be removed as an outpatient, once normal 
oral intake has resumed.
Early satiety, postprandial abdominal pain and weight loss are 
frequently experienced by patients with gastric cancer. Surgical 
resection usually requires a total gastrectomy with an oesophageal 
anastomosis. Signifi cant weight loss; dumping syndrome; fat 
malabsorption; and iron, calcium and vitamin B12 defi ciency 
commonly occur postoperatively. Fluid nutritional supplements and 
small frequent meals may be benefi cial to post-surgical patients with 
dumping and bloating. Increasing the pectin content in the diet to 
slow down gastric emptying and minimise fall in postprandial blood 
glucose levels is helpful and improves the nutritional management of 
such patients.21 Steatorrhea may occur due to secondary pancreatic 
insuffi ciency, and could be treated with pancreatic enzyme 
supplementation.22 Vitamin and mineral defi ciencies should be 
prevented and treated with adequate oral supplementation of iron, 
vitamin C and B12. Nocturnal jejunal feeding should be considered 
in patients who continue to lose weight despite dietary adjustments/
supplements.1
Treatment of colorectal cancer involves resection of the affected 
segment of the bowel. Postoperative chemotherapy is usually 
tolerated well, with few nutrition-related side effects. If large 
sections of the right colon are resected, and the ileocaecal valve 
is compromised, postprandial diarrhoea may result. If more than 
60 cm of the terminal ileum is resected, vitamin B12 supplementation 
will be necessary.1
Parenteral nutrition
Indications for parenteral nutrition include small bowel obstruction, 
which may develop due to tumour growth; severe diarrhoea 
and malabsorption during the active treatment of the disease; 
gastrointestinal haemorrhage; treatment of fi stulae; and as a 
supportive care for severely malnourished patients. PN is not 
generally indicted for patients with non-obstructive disease or if the 
duration for nutritional support is suspected to be shorter than seven 
days. There is no evidence to support that PN improves the outcome 
of chemotherapy or radiation-related treatment or the survival of 
patients with cancer.23 Optimal nutrition does however affect the 
patient’s quality of life.
Peripheral parenteral nutrition can be used when short-term 
nutritional support is needed for a period of less than seven to 
ten days.1
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How much?
Several studies have investigated energy expenditure and protein 
needs of cancer patients. Cancer patients with active disease 
may require as much as 1,2–1,5 times increased energy intake 
compared to normal resting energy expenditure. Energy needs 
can be calculated up to 168 kJ/kg/day of ideal body weight, and 
1–1,5 g/kg of ideal body weight for protein are usually suffi cient for 
most adult cancer patients. Most hospitalised cancer patients only 
require nutritional support for up to two weeks.1
Monitoring safety
PN will not have any signifi cant value to the patient if not used and 
monitored appropriately. Monitoring the therapy and making regular 
adjustments as required is imperative to achieve the desired goal/
benefi t. Patients should be weighed daily, and accurate fl uid intake 
and output should be recorded. Urine output should be more than 
1000 ml per 24 hours in order to ensure adequate hydration of 
the patient. A weight gain of more than one to two kilograms per 
week usually indicates fl uid retention. This may occur in the fi rst 
two weeks after PN is initiated. Diuretic therapy is occasionally 
required. Electrolytes and triglyceride levels should be monitored 
twice weekly.24
The human body adapts to weight loss and starvation by reducing 
resting energy expenditure. When large amounts of energy and 
carbohydrates are supplied to a malnourished cancer patient at 
too rapid a pace, refeeding syndrome may result.25 Refeeding is a 
potentially life-threatening complication of both PN and TEN when 
carbohydrate intake stimulates pancreatic insulin release, which 
results in the fl ow of potassium and magnesium to the intercellular 
space, with the possibility of cardiac arrhythmias as an adverse 
outcome. Prevention of refeeding syndrome is possible by using 
a mixed carbohydrate, protein and lipid formula, and gradually 
increasing the rate of administration.
Enteral nutrition
Enteral nutrition is recommended in the absence of bowel obstruction, 
high output fi stula, or toxic megacolon. Because of postoperative 
gastroparesis, jejunal feeding may be preferred for specifi c cancer 
patients. TEN is generally started at a relatively slow rate (40 ml/h) 
and gradually increased eight hourly until the nutritional goal is 
reached. In severely malnourished patients, the infusion rate may 
have to be started at an even slower rate so as to avoid the refeeding 
syndrome. No standard commercial formula provides suffi cient free 
water to meet the patient’s daily fl uid requirements. Small frequent 
bolus amount of free water is required to meet patient needs.1 
Percutaneous endoscopic gastroscopy (PEG) feeding is often an 
effective and emotionally acceptable means of long term TEN.
Regular monitoring and adjustments to nutritional prescriptions is 
imperative in order to achieve nutritional goals which will improve 
the patient’s nutritional status.
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